Exactech Masters Course Sets Standard in Specialized Medical Education
September 08 2015 - 9:27AM
Business Wire
Global Leaders Present Data Supporting the
Equinoxe® Shoulder and Address Key Topics in Shoulder
Reconstruction
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone
and joint restoration products for hip, knee, shoulder and spine,
hosted more than 70 shoulder specialists at its recent Shoulder
Masters Course in San Francisco, Calif.
Twenty-one presentations highlighted new insights about shoulder
arthroplasty, including 11 clinical outcome studies. Attendees
included surgeons from seven countries, including the United
States, Canada, France, Italy, Brazil, Korea and the United
Kingdom.
“The Masters Course in Shoulder Arthroplasty embodies Exactech’s
vision to deliver solutions that improve patient outcomes,” said
Darin Johnson, Vice President of Marketing for Exactech Extremities
and Hip. “Global thought leaders presented data collected over the
past 10 years demonstrating the results of the Equinoxe® products.
Panel discussions and open questions from the floor put the
spotlight on current clinical challenges that will fuel development
for the next decade.”
“Exactech set a new standard for medical education with this
Shoulder Masters Course,” said Emilie Cheung, MD, Associate
Professor of Orthopaedic Surgery at the Stanford University Medical
Center. “The clinical outcomes were impressive, and the faculty of
experienced orthopaedic surgeons provided insights on ways to deal
with tough challenges in the O.R.”
One of the highlighted studies included a retrospective review
of patient outcomes and complications for 51 consecutive proximal
humerus (upper arm) fractures that were treated with the Equinoxe
Fracture Plate. Lead researcher Kenneth Egol, MD, New York
University - Hospital for Joint Diseases, presented results showing
that the patient’s postoperative flexion and rotation outcomes
compare favorably to published reports of other locking plate
systems.
David Collins, MD, Arkansas Specialty Orthopaedics/Central
Arkansas Veterans Health Care System, presented a large-scale
clinical outcome study which demonstrated that patients with
scapular notching, an erosion of the scapula (shoulder blade) that
can occur with reverse shoulder arthroplasty, experience
significantly poorer outcomes and a greater complication rate than
patients without scapular notching at a similar average
postoperative follow-up.
Additionally, Felix (Buddy) Savoie, MD, Tulane University School
of Medicine, discussed a minimally-invasive, tissue preserving
approach which provides adequate exposure for shoulder replacement
surgery and provides a decreased risk of postoperative failure
(rupture or atrophy) of the subscapularis tendon.
The course’s 15 faculty members included Greg Bauer, MD; Emilie
Cheung, MD; David Collins, MD; Lynn Crosby, MD; Kenneth Egol, MD;
Pierre-Henri Flurin, MD; Richard Friedman, MD; Sean Grey, MD;
Richard Jones, MD; Curtis Noel, MD; Howard Routman, DO; Felix
(Buddy) Savoie, MD; Ryan Simovitch, MD; Thomas Wright, MD; and
Joseph Zuckerman, MD. The proceedings from this course will be
published in the Bulletin of the Hospital for Joint Diseases at the
end of this year.
The scope of the studies referenced is specific to Equinoxe
implants and performed by Exactech consultants.
About Equinoxe® Shoulder
Exactech’s Equinoxe Shoulder System has been one of the fastest
growing systems since its introduction 10 years ago. No matter what
challenges a surgeon may face, the system offers true
“reversatility,” designed to enable surgeons to convert from either
a primary shoulder or fracture hemi to a reverse shoulder without
stem removal. It also is the only system that offers augmented
glenoid solutions for both the anatomic and reverse.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech, Inc. can be found at
http://www.exac.com. Copies of Exactech’s press releases, SEC
filings, current price quotes and other valuable information for
investors may be found at http://www.exac.com and
http://www.hawkassociates.com.
An investment profile on Exactech may be found at
http://www.hawkassociates.com/profile/exac.cfm. To receive future
releases in e-mail alerts, sign up at
http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which represent
the company’s expectations or beliefs concerning future events of
the company’s financial performance. These forward-looking
statements are further qualified by important factors that could
cause actual results to differ materially from those in the
forward-looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of
third party manufacturers to produce components on a basis which is
cost-effective to the company, market acceptance of the company’s
products and the effects of government regulation. Results actually
achieved may differ materially from expected results included in
these statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150908006013/en/
Exactech, Inc.Investor contactsJody Phillips,
352-377-1140Executive Vice President of Finance &Chief
Financial OfficerorHawk AssociatesJulie Marshall or Frank Hawkins,
305-451-1888E-mail: EXAC@hawkassociates.com
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Apr 2024 to May 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From May 2023 to May 2024